Alemtuzumab (MabCampath)

Handbook of Therapeutic Antibodies

Volumn 3, Issue , 2008, Pages 733-777

  Elter, Thomas ^a   Engert, Andreas ^a   Hallek, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Alemtuzumab; Alkylating agents; Antibodies; Clinical trials; Principles

Indexed keywords

EID: 84889300781     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619740.ch28     Document Type: Chapter

References (77)

1. Albitar, M., Do, K.A., Johnson, M.M., Giles, F.J., Jilani, I., O'Brien, S., Cortes, J., Thomas, D., Rassenti, L.Z., Kipps, T.J., Kantarjian, H.M., Keating, M. (2004).Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 101: 999-1008.
2. Brett, S.J., Baxter, G., Cooper, H., Rowan, W., Regan, T., Tite, J., Rapson, N. (1996)Emergence of CD52-, glycosylphosphatidylinositol-anchordeficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment. Int Immunol 8: 325-334.CAMPATH (Alemtuzuma) product information, 2004.
3. Chakrabarti, S., Mackinnon, S., Chopra, R., Kottaridis, P.D., Peggs, K., O'Gorman, P., Chakraverty, R., Marshall, T., Osman, H., Mahendra, P., Craddock, C., Waldmann, H., Hale, G., Fegan, C.D., Yong, K., Goldstone, A.H., Linch, D.C., Milligan, D.W. (2002).High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99: 4357-4363.
4. Chakraverty, R., Peggs, K., Chopra, R., Milligan, D.W., Kottaridis, P.D., Verfuerth, S., Geary, J., Thuraisundaram, D., Branson, K., Chakrabarti, S., Mahendra, P., Craddock, C., Parker, A., Hunter, A., Hale, G., Waldmann, H., Williams, C.D., Yong, K., Linch, D.C., Goldstone, A.H., Mackinnon, S. (2002).Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood, 99: 1071-1078.
5. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S., Rai, K.R. (1996).National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990-4997.
6. Cheson, B.D., Bennett, J.M., Rai, K.R., Grever, M.R., Kay, N.E., Schiffer, C.A., Oken, M.M., Keating, M.J., Boldt, D.H., Kempin, S.J., et al. (1988).Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 29: 152-163.
7. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R., Canellos, G.P. (1999)Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17: 1244.
8. Ciancio, G., Burke, G.W., Gaynor, J.J., Mattiazzi, A., Roohipour, R., Carreno, M.R., Roth, D., Ruiz, P., Kupin, W., Rosen, A., Esquenazi, V., Tzakis, A.G., Miller, J. (2004).The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 78: 426-433.
9. Dearden, C.E., Matutes, E., Cazin, B., Tjonnfjord, G.E., Parreira, A., Nomdedeu, B., Leoni, P., Clark, F.J., Radia, D., Rassam, S.M., Roques, T., Ketterer, N., Brito-Babapulle, V., Dyer, M.J., Catovsky, D. (2001).High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98: 1721-1726.
10. Dyer, M.J., Hale, G., Hayhoe, F.G., Waldmann, H. (1989).Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73: 1431-1439.
11. Elter, T., Borchmann, P., Schulz, H., Reiser, M., Trelle, S., Schnell, R., Jensen, M., Staib, P., Schinkothe, T., Stutzer, H., Rech, J., Gramatzki, M., Aulitzky, W., Hasan, I., Josting, A., Hallek, M., Engert, A. (2005).Fludarabine in combination with alemtuzumab Is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23: 7024-7031.
12. Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., MacDonald, A.P., Repp, R., Schetelig, J., Seipelt, G., Osterborg, A. (2004).A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapyrefractory peripheral T-cell lymphomas. Blood 103: 2920-2924.
13. Faderl, S., Thomas, D.A., O'Brien, S., Garcia-Manero, G., Kantarjian, H.M., Giles, F.J., Koller, C., Ferrajoli, A., Verstovsek, S., Pro, B., Andreeff, M., Beran, M., Cortes, J., Wierda, W., Tran, N., Keating, M.J. (2003).Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101: 3413-3415.
14. Ferrajoli, A., O'Brien, S.M., Cortes, J.E., Giles, F.J., Thomas, D.A., Faderl, S., Kurzrock, R., Lerner, S., Kontoyiannis, D.P., Keating, M.J. (2003).phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98: 773-778.
15. Fløisand, Y., Brinch, L., Gedde-Dahl, T., Tjonnfjord, G.E. (2004).[Treatment of Tcell prolymphocytic leukemia with monoclonal anti-CD52 antibody (alemtuzumab]. Tidsskr Nor Laegeforen 124: 768-770.
16. Gautschi, O., Blumenthal, N., Streit, M., Solenthaler, M., Hunziker, T., Zenhausern, R. (2004).Successful treatment of chemotherapy-refractory Sezary syndrome with alemtuzumab (Campath-1H). Eur JHaematol 72: 61-63.
17. Gilleece, M.H. and Dexter, T.M. (1993).Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82: 807-812.
18. Ginaldi, L., De, M.M., Matutes, E., Farahat, N., Morilla, R., Dyer, M.J., Catovsky, D. (1998).Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 22: 185-191.
19. Golay, J., Manganini, M., Rambaldi, A., Introna, M. (2004).Effect of alemtuzumab on neoplastic B cells. Haematologica 89: 1476-1483.
20. Greenwood, J., Clark, M., Waldmann, H. (1993).Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 23: 1098-1104.
21. Gruessner, R.W., Kandaswamy, R., Humar, A., Gruessner, A.C., Sutherland, D.E. (2005).Calcineurin inhibitor-and steroidfree immunosuppression in pancreaskidney and solitary pancreas transplantation. Transplantation 79: 1184-1189.
22. Hale, G. (2001).The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 3: 137-143.
23. Hale, G., Waldmann, H. (1994).Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 13: 597-611.
24. Hale, G., Bright, S., Chumbley, G., Hoang, T., Metcalf, D., Munro, A.J., Waldmann, H. (1983).Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 62: 873-882.
25. Hale, G., Swirsky, D.M., Hayhoe, F.G., Waldmann, H. (1983).Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med 1: 321-334.
26. Hale, G., Clark, M., Waldmann, H. (1985).Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibodydependent cell-mediated cytotoxicity with human lymphocytes. J Immunol 134: 3056-3061.
27. Hale, G., Dyer, M.J., Clark, M.R., Phillips, J.M., Marcus, R., Riechmann, L., Winter, G., Waldmann, H. (1988).Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2: 1394-1399.
28. Hale, G., Zhang, M.J., Bunjes, D., Prentice, H.G., Spence, D., Horowitz, M.M., Barrett, A.J., Waldmann, H. (1998).Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 92: 4581-4590.
29. Hale, G., Rebello, P., Brettman, L.R., Fegan, C., Kennedy, B., Kimby, E., Leach, M., Lundin, J., Mellstedt, H., Moreton, P., Rawstron, A.C., Waldmann, H., Österborg, A., Hillmen, P. (2004).Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104: 948-955.
30. Hillmen, P., Skotnicki, A., Robak, T., Jaksic, B., Dmoszynska, A., Sirard, C., Mayer, J. (2006)Preliminary phase 3 efficacy and safety of alemtuzumab vs chlorambucil as front-lint therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL). J Clin Oncol 24 (SUPPL.1), 339s, Abstract 6511.
31. Isaacs, J.D., Manna, V.K., Rapson, N., Bulpitt, K.J., Hazleman, B.L., Matteson, E.L., St Clair, E.W., Schnitzer, T.J., Johnston, J.M. (1996).CAMPATH-1H in rheumatoid arthritis-an intravenous dose-ranging study. Br J Rheumatol 35: 231-240.
32. Keating, M.J., Cazin, B., Coutre, S., Birhiray, R., Kovacsovics, T., Langer, W., Leber, B., Maughan, T., Rai, K., Tjonnfjord, G., Bekradda, M., Itzhaki, M., Herait, P. (2002).Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 20: 205-213.
33. Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B., Rai, K.R. (2002).Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99: 3554-3561.
34. Keating, M., O'Brien, S., Kontoyiannis, D., Plunkett, W., Koller, C., Beran, M., Lerner, S., Kantarjian, H. (2002).Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 43: 1755-1762.
35. Keating, M., Coutre, S., Rai, K., Osterborg, A., Faderl, S., Kennedy, B., Kipps, T., Bodey, G., Byrd, J.C., Rosen, S., Dearden, C., Dyer, M.J., Hillmen, P. (2004).Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 4: 220-227.
36. Kennedy, B., Rawstron, A., Carter, C., Ryan, M., Speed, K., Lucas, G., Hillmen, P. (2002).Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99: 2245-2247.
37. Kennedy, G.A., Seymour, J.F., Wolf, M., Januszewicz, H., Davison, J., McCormack, C., Ryan, G., Prince, H.M. (2003).Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol 71: 250-256.
38. Khorana, A., Bunn, P., McLaughlin, P., Vose, J., Stewart, C., Czuczman, M.S. (2001).A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma 41: 77-87.
39. Kirchhoff, C. (1996).CD52 is the 'major maturation-associated' sperm membrane antigen. Mol Hum Reprod 2: 9-17.
40. Knechtle, S.J., Fernandez, L.A., Pirsch, J.D., Becker, B.N., Chin, L.T., Becker, Y.T., Odorico, J.S., D'alessandro, A.M., Sollinger, H.W. (2004).Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 136: 754-760.
41. Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S., Peggs, K., Verfuerth, S., Pettengell, R., Marsh, J.C., Schey, S., Mahendra, P., Morgan, G.J., Hale,G., Waldmann, H., de Elvira, M.C., Williams, C.D., Devereux, S., Linch, D.C., Goldstone, A.H., Mackinnon, S. (2000).In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96: 2419-2425.
42. Kumar, S., Kimlinger, T.K., Lust, J.A., Donovan, K., Witzig, T.E. (2003).Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood 102: 1075-1077.
43. Laporte, J.P., Isnard, F., Garderet, L., Fouillard, L., Gorin, N.C. (2004).Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia 18: 1557-1558.
44. Lozanski, G., Heerema, N.A., Flinn, I.W., Smith, L., Harbison, J., Webb, J., Moran, M., Lucas, M., Lin, T., Hackbarth, M.L., Proffitt, J.H., Lucas, D., Grever, M.R., Byrd, J.C. (2004).Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103: 3278-3281.
45. Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., Epenetos, A., Gisselbrecht, C., Huhn, D., Jaeger, U., Thomas, J., Marcus, R., Nissen, N., Poynton, C., Rankin, E., Stahel, R., Uppenkamp, M., Willemze, R., Mellstedt, H. (1998).CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.J Clin Oncol 16: 3257-3263.
46. Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P.A., Celsing, F., Hjalmar, V., Mollgard, L., Rebello, P., Hale, G., Waldmann, H., Mellstedt, H., Osterborg, A. (2002).phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100: 768-773.
47. Lundin, J., Hagberg, H., Repp, R., Cavallin-Stahl, E., Freden, S., Juliusson, G., Rosenblad, E., Tjonnfjord, G., Wiklund, T., Osterborg, A. (2003).phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101: 4267-4272.
48. Lundin, J., Porwit-MacDonald, A., Rossmann, E.D., Karlsson, C., Edman, P., Rezvany, M.R., Kimby, E., Osterborg, A., Mellstedt, H. (2004).Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 18: 484-490.
49. Montillo, M., Cafro, A.M., Tedeschi, A., Brando, B., Oreste, P., Veronese, S., Rossi, V., Cairoli, R., Pungolino, E., Morra, E. (2002).Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 87: 695-700.
50. Montillo, M., Tedeschi, A., Miqeuleiz, S., Veronese, S., Rossi, V., Cairoli, R., Intropido L., Ricci, F., Colosimo, A., Scarpati, B., Montagna, M., Nichelatti, M., Regazzi, M., Morra, E. (2006).Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 24: 2337-2342.
51. Moreton, P., Kennedy, B., Lucas, G., Leach, M., Rassam, S.M., Haynes, A., Tighe, J., Oscier, D., Fegan, C., Rawstron, A., Hillmen, P. (2005).Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23: 2971-2979.
52. Naparstek, E., Or, R., Nagler, A., Cividalli, G., Engelhard, D., Aker, M., Gimon, Z., Manny, N., Sacks, T., Tochner, Z., et al. (1995).T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89: 506-515.
53. Nückel, H., Frey, U.H., Roth, A., Duhrsen, U., Siffert, W. (2005).Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibodydependent cellular cytotoxicity. Eur JPharmacol 514: 217-224.
54. O'Brien, S.M., Kantarjian, H.M., Thomas, D.A., Cortes, J., Giles, F.J., Wierda, W.G., Koller, C.A., Ferrajoli, A., Browning, M., Lerner, S., Albitar, M., Keating, M.J. (2003).Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98: 2657-2663.
55. Österborg, A., Fassas, A.S., Anagnostopoulos, A., Dyer, M.J., Catovsky, D., Mellstedt, H. (1996).Humanized CD52 monoclonal antibody Campath-1H as firstline treatment in chronic lymphocytic leukaemia. Br J Haematol 93: 151-153.
56. Österborg, A., Dyer, M.J.S., Bunjes, D., Pangalis, G.A., Bastion, Y., Catovsky, D., Mellstedt, H. (1997).phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 15: 1567-1574.
57. Perez-Simon, J.A., Kottaridis, P.D., Martino, R., Craddock, C., Caballero, D., Chopra, R., Garcia-Conde, J., Milligan, D.W., Schey, S., Urbano-Ispizua, A., Parker, A., Leon, A., Yong, K., Sureda, A., Hunter, A., Sierra, J., Goldstone, A.H., Linch, D.C., San Miguel, J.F., Mackinnon, S. (2002).Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100: 3121-3127.
58. Perkins, J.G., Flynn, J.M., Howard, R.S., Byrd, J.C. (2002).Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 94: 2033-2039.
59. Piccaluga, P.P., Martinelli, G., Malagola, M., Rondoni, M., Bonifazi, F., Bandini, G., Visani, G., Baccarani, M. (2005)Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. Leukemia 19: 135.
60. Rai, K.R., Stephenson, J. (2001)Campath-1H: emerging frontline therapy in chronic lymphocytic leukemia. Parthenon Publishing, Pearl River, NY, p. 62.
61. Rai, K.R., Freter, C.E., Mercier, R.J., Cooper, M.R., Mitchell, B.S., Stadtmauer, E.A., Santabarbara, P., Wacker, B., Brettman, L. (2002).Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20: 3891-3897.
62. Ravandi, F. and Faderl, S. (2006).Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk Res 30: 103-105.
63. Rawstron, A.C., Kennedy, B., Evans, P.A., Davies, F.E., Richards, S.J., Haynes, A.P., Russel, N.H., Hale, G., Morgan, G.J., Jack, A.S., Hillmen, P. (2001).Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98: 29-35.
64. Rebello, P.R., Hale, G., Friend, P.J., Cobbold, S.P., Waldmann, H. (1999).Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation 68: 1417-1420.
65. Rebello, P., Cwynarski, K., Varughese, M., Eades, A., Apperley, J.F., Hale, G. (2001).Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 3: 261-267.
66. Riechmann, L., Clark, M., Waldmann, H., Winter, G. (1988)Reshaping human antibodies for therapy. Nature 332: 323-327. Rituxan (Rituxima) product information, 2005. Genentech, South San Francisco, CA.
67. Rowan, W., Tite, J., Topley, P., Brett, S.J. (1998).Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B-and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 95: 427-436.
68. Stanglmaier, M., Reis, S., Hallek, M. (2004).Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 83: 634-645.
69. Sundberg, A.K., Roskopf, J.A., Hartmann, E.L., Farney, A.C., Rohr, M.S., Stratta, R.J. (2005).Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation. Transplant Proc 37: 1294-1296.
70. Uppenkamp, M., Engert, A., Diehl, V., Bunjes, D., Huhn, D., Brittinger, G. (2002).Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high-and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann Hematol 81: 26-32.
71. Waldmann, H., Polliak, A., Hale, G., Or, R., Cividalli, G., Weiss, L., Weshler, Z., Samuel, S., Manor, D., Brautbar, C., et al. (1984).Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat antihuman lymphocyte antibody (CAMPATH-1). Lancet 2: 483-486.
72. Watson, C.J., Bradley, J.A., Friend, P.J., Firth, J., Taylor, C.J., Bradley, J.R., Smith, K.G., Thiru, S., Jamieson, N.V., Hale, G., Waldmann, H., Calne, R. (2005). Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 5: 1347-1353.
73. Wendtner, C.M., Ritgen, M., Schweighofer, C.D., Fingerle-Rowson, G., Campe, H., Jager, G., Eichhorst, B., Busch, R., Diem, H., Engert, A., Stilgenbauer, S., Dohner, H., Kneba, M., Emmerich, B., Hallek, M. (2004).Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18: 1093-1101.
74. Xia, M.Q., Hale, G., Lifely, M.R., Ferguson, M.A., Campbell, D., Packman, L., Waldmann, H. (1993)Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 293 (PT 3): 633-640.
75. Zeitlinger, M.A., Schmidinger, M., Zielinski, C.C., Chott, A., Raderer, M. (2005).Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphom) refractory to chemotherapy with the CD-52 antibody alemtuzumab. Leuk Lymphoma 46: 771-774.
76. Zhang, Z., Zhang, M., Goldman, C.K., Ravetch, J.V., Waldmann, T.A. (2003).Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res 63: 6453-6457.
77. Zinzani, P.L., Alinari, L., Tani, M., Fina, M., Pileri, S., Baccarani, M. (2005).Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 90: 702-703.